key: cord-1051946-4cv5fh2w
authors: Puéchal, Xavier; Cottin, Vincent; Faguer, Stanislas; Guillevin, Loïc; Jourde-Chiche, Noémie; Karras, Alexandre; Mouthon, Luc; Néel, Antoine; Pugnet, Gabriel; Samson, Maxime; Taille, Camille; Terrier, Benjamin
title: French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis
date: 2021-12-24
journal: Presse Med
DOI: 10.1016/j.lpm.2021.104107
sha: 80d4ac57cc50b49323c336835801fa44beffd29e
doc_id: 1051946
cord_uid: 4cv5fh2w

nan

There are ongoing discussions regarding the timing of SARS-CoV-2 vaccination of patients with chronic inflammatory diseases. It has been reported that patients who received rituximab (RTX) treatment and who no longer have detectable peripheral B cells in their blood are not able to build up an antibody response after SARS-CoV-2 vaccination whereas those with detectable B cells can mount antibody responses (3) . These data were confirmed by prospective study cohorts of patients with chronic inflammatory diseases who developed gradual recovery of antibody response to vaccination 9 months after treatment with RTX (4, 5) . Delaying RTX treatment, especially in case of maintenance treatment, may thus be justified in patients with stable disease until peripheral B cells repopulate to allow development of neutralizing antibodies in response to vaccination.

To help clinicians put this data into clinical practice, the Scientific Council of the FVSG adopted a set of recommendations for the management of SARS-CoV-2 vaccination and prophylaxis in patients with systemic vasculitis.

First, vaccination against the SARS-CoV-2 is strongly recommended in patients with vasculitis of any type (including ANCA-associated vasculitis). Severely immunocompromised patients are at very high risk for severe forms of COVID-19. Immunosuppressive treatments can affect vaccine response and induce a defect in the production of neutralizing antibodies and/or alter T lymphocyte response (even if the latter is not routinely assessed). In addition, vaccine-induced vasculitis flare is very rare and could be adequately diagnosed with close monitoring and managed.

Second, among patients on immunosuppressive therapy, those receiving RTX treatment are more likely to experience a severe form of COVID-19 (6,7) and have a lower probability of developing a protective antibody titers, especially when they have no detectable B lymphocytes at the time of vaccination (3, 4) . On the other hand, the probability of developing an anti-SARS-CoV-2 humoral immune response in the course of RTX treatment is greater if the vaccination is carried out after Blymphocytes repopulation. For these reasons, the systematic injection of a 3rd dose of vaccine is recommended in patients on immunosuppressants to complete initial vaccination schedule, at least 4 weeks after the second dose, or as soon as possible for people who have already exceeded this time.

The FVSG recommends a case-by-case discussion of delaying the first RTX infusion as part of induction therapy or spacing infusions as part of maintenance therapy, depending on the degree of clinical emergency, susceptibility to severe SARS-CoV-2 infection, anti-S protein antibody levels, and B cell count.

Third, in a patient receiving RTX who does not have a sufficient antibody response after 3 doses of vaccine, the T lymphocyte response appears to be preserved (3) and probably provides some protection (even if it remains difficult to correlate with a potential clinical benefit), and the effectiveness of the vaccine booster (from 3 months after the 3rd dose) remains unclear. However, its realization seems important to discuss, ideally at the time of B-cell repopulation if it is possible to postpone the RTX infusion (especially in the case of maintenance treatments).

Fourth, in all cases, monitoring of the antibody response is essential to identify patients with no or insufficient antibody response, potentially eligible for cocktails of monoclonal antibodies directed against SARS-CoV-2 for pre-or post-exposure prophylaxis. Recommendations developed by the FVSG are intended to inform particular patterns of practice and not to dictate the care of a particular patient, with the ultimate determination regarding its application to be made by the physician in light of each patient's individual circumstances and preferences. Due to the rapidly expanding information and evolving evidence related to COVID-19, which may lead to modification of some guidance statements over time, it is anticipated that updated versions of this recommendation will have to be published.

Suite à la publication des recommandations françaises sur la prise en charge des vascularites systémiques nécrosantes (1) 

French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance

SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cellmediated immunity

Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2 : a prospective cohort study

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System

Association Between Risk of COVID-19 infection in nonimmune individuals and COVID-19 immunity in their family members

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection